A Phase II Trial of Chemotherapy plus Pembrolizumab in patients with advanced NSCLC previously treated with PD-1 or PD-L1 Inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029

Learn more:

• clinicaltrials.gov: #NCT03083808
• See Study Locations on Big Ten CRC Website